Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up Phase I/II results will be discussed with US and...
coAAV-mediated gene transfer holds promise for expanding the scope of ocular diseases treatable via suprachoroidal administration Data to be presented in oral session at ASGCT 2024 Paris,...
Paris, France, April 25, 2024 “ eyeDNA Therapeutics (˜eyeDNA™), a newly created subsidiary of Coave Therapeutics (˜Coave™), a genetic medicine company focused on developing life-changing therapies,...
Paris, France, March 27, 2024 “ Coave Therapeutics (˜Coave™), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following...
Coave Receives Grant from the ALS Association to Advance its CTx-TFEB Program
Paris, France, October 12th, 2023“ Coave Therapeutics (˜Coave™), a genetic medicine company focused on developing life-changing therapies, announces the formation of its new Scientific Advisory Board...
Paris, France, September 28, 2023 “ Coave Therapeutics (˜Coave™), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
Paris, France, September 21, 2023 “ Coave Therapeutics (˜Coave™), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile Positive results from the study to date support preparations for a...
Paris, France, May 17, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announces that it will participate at the following conferences: